<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699827</url>
  </required_header>
  <id_info>
    <org_study_id>TM1</org_study_id>
    <nct_id>NCT02699827</nct_id>
  </id_info>
  <brief_title>Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia</brief_title>
  <official_title>Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Sayed Abdelhafez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the effect of adding magnesium sulphate epidurally as an
      adjunct to levobupivacaine on the quality of anesthesia and perioperative pain relief in
      patients with preeclampsia undergoing elective caesarian section (CS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women with preeclampsia undergoing elective CS in will be included in the study. All
      patients participating in the study will be randomly divided into two groups; magnesium
      sulphate group (study group) and placebo group (control group). Patients in the study group
      will receive epidural 20 ml levobupivacaine hydrochloride 0.5% plus 5 ml magnesium sulphate
      10% (500 mg) while patients in the control group will received epidural 20 ml levobupivacaine
      hydrochloride 0.5% plus 5 ml saline 0.9%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain-free period</measure>
    <time_frame>24 hours after the epidural anesthesia</time_frame>
    <description>The time from reaching sensory block to onset of pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Magnesium sulphate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive epidural levobupivacaine hydrochloride + magnesium sulphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive epidural levobupivacaine hydrochloride + saline 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine hydrochloride</intervention_name>
    <description>Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%</description>
    <arm_group_label>Magnesium sulphate group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Chirocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>Patients will receive epidural 5 ml magnesium sulphate 10%</description>
    <arm_group_label>Magnesium sulphate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>Patients will receive epidural 5 ml saline 0.9%</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with preeclampsia undergoing elective CS.

        Exclusion Criteria:

          -  Age &lt; 20 or &gt; 35 years.

          -  Height &lt; 150 or &gt; 180 cm.

          -  Body mass index (BMI) &gt; 35 kg/m2.

          -  Active labor.

          -  Multifetal pregnancy.

          -  Fetal distress.

          -  Medical conditions complicating pregnancy.

          -  HELLP syndrome.

          -  Thrombocytopenia.

          -  Hepatic or renal impairment.

          -  Pulmonary edema or cyanosis.

          -  Placenta previa.

          -  Vaginal bleeding or placental abruption.

          -  Contraindication for central neuraxial block.

          -  History of adverse reaction to any study medication.

          -  History of analgesic use.

          -  Magnesium therapy.

          -  Chronic pain syndrome.

          -  Presence of communication difficulties preventing reliable assessment.

          -  Refusal to undergo regional anesthesia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamer Elmetwally, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reem A Elsharkawy, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waleed El-refaie, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alaa Wageeh, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salwa S Hays, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>June 3, 2017</last_update_submitted>
  <last_update_submitted_qc>June 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed Sayed Abdelhafez</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Levobupivacaine</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Epidural</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

